We have turned a corner: What the ARUK conference told us about the future of dementia treatment
The CF Life Sciences team attended the ARUK 2026 [...]
NICE rejects groundbreaking Alzheimer’s drugs: What it means for the UK
In a move that has triggered disappointment across the [...]
A new era in Alzheimer’s diagnosis: What the FDA’s first approved blood test means for the UK
On 16 May 2025, the U.S. Food and Drug [...]
